Abstract
Background
Daratumumab and isatuximab are anti-CD38 monoclonal antibodies indicated for the treatment of multiple myeloma. These agents can increase the risk of infectious complications, including viral infections. Cases of hepatitis B virus (HBV) reactivation have been reported in the literature in patients receiving anti-CD38 monoclonal antibody-based therapies.
Aim
The objective of this analysis was to determine if the association between anti-CD38 monoclonal antibody exposure and the development of hepatitis B reactivation had a detectable reporting signal in the United States Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS).
Method
We conducted a post marketing pharmacovigilance analysis by querying the FAERS for reports of HBV reactivation with daratumumab or isatuximab exposure reported between 2015 and 2022. Disproportionality signal analysis was conducted by calculating reporting odds ratios (RORs).
Results
Sixteen cases of hepatitis B virus reactivation were reported in the FAERS database among patients receiving daratumumab or isatuximab reported between 2015 and 2022. The ROR for HBV reactivation was statistically significant for both daratumumab (ROR 4.76, 95% CI 2.76–8.22) and isatuximab (ROR 9.31, 95% CI 3.00–28.92).
Conclusion
Overall, our analysis demonstrates a significant reporting signal for HBV reactivation with daratumumab and isatuximab.
This is a preview of subscription content, log in via an institution to check access.
References
Facon T, Kumar SK, Plesner T, et al. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(11):1582–96.
Dimopoulos MA, Quach H, Mateos MV, et al. Carfilzomib, dexamethasone and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet. 2020;396(10245):186–97.
Richardson PG, Perrot A, San-Miguel J, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study. Lancet Oncol. 2022;23(3):416–27.
Vassilopoulos S, Vassilopoulos A, Kalligeros M, et al. Cumulative incidence and relative risk of infection in patients with multiple myeloma treated with anti-CD38 monoclonal antibody-based regimens: a systematic review and meta-analysis. Open Forum Infect Dis. 2022. https://doi.org/10.1093/ofid/ofac574.
Mateos MV, Nahi H, Legiec W, et al. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomized, phase 3 trial. Lancet Haematol. 2020;7(5):e370–80.
Lee SK, Sung PS, Park SS, et al. Reactivation of resolved hepatitis B after daratumumab for multiple myeloma. Clin Infec Dis. 2021;73(6):e1372–5.
Kikuchi T, Kusumoto S, Tanaka Y, et al. Hepatitis B virus reactivation in a myeloma patient with resolved infection who received daratumumab-containing salvage chemotherapy. J Clin Exp Hematop. 2020;60(2):51–4.
Mustafayev K, Torres H. Hepatitis B virus and hepatitis C virus reactivation in cancer patients receiving novel anticancer therapies. Clin Microbiol Infect. 2022;28(1):1321–7.
Chiu C-Y, Patel K, Thomas SK, et al. (2022) Hepatitis B virus reactivation in patients with past HBV infection receiving anti-CD38 monoclonal antibodies. Hepatol Int. 2023;17:509–11.
Maintenance and Support Services Organization [Homepage on the Internet] (2013) Medical dictionary for regulatory activities. McLean (VA): MedDRA MSSO; http://www.meddra.org. Accessed 10 Apr 2023.
Bate A, Evans SJW. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18(6):427–36.
Arnall JR, Maples KT, Harvey RD, et al. Daratumumab for the treatment of multiple myeloma: a review of clinical applicability and operational considerations. Ann Pharmacother. 2022;56(8):927–40.
Loomba R, Liang TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions. Gastroenterology. 2017;152:1297–309.
Zhang S, Zhao J, Zhang Z. Humoral immunity, the underestimated player in hepatitis B. Cell Mol Immunol. 2018;15:645–8.
Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. J Clin Oncol. 2020;38(31):3698–715.
Atilla PA, Yalciner M, Atilla E, et al. Hepatitis B reactivation rate and fate among multiple myeloma patients receiving regimens containing lenalidomide and/or bortezomib. Turk J Haematol. 2019;36(4):266–73.
Funding
The authors received no funding in the support of this work.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
Dr. Moore reports advisory board participation with Pfizer, Janssen, and AstraZeneca. Dr. Arnall reports speaker’s bureau with NovoNordisk and advisory board participation with CTI BioPharma and Hema Biologics.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Moore, D.C., Elmes, J.B., Arnall, J.R. et al. Hepatitis B reactivation in patients with multiple myeloma treated with anti-CD38 monoclonal antibody-based therapies: a pharmacovigilance analysis. Int J Clin Pharm 45, 1492–1495 (2023). https://doi.org/10.1007/s11096-023-01608-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11096-023-01608-7